Bristol-Myers Squibb Company (BMY)
Buy The Drop On These 6% Dividend Value Picks
AI stocks like Nvidia, Super Micro Computer, and Dell Technologies are leading the market but may be in bubble territory. Value stocks like W.P. Carey and Bristol Myers Squibb offer beaten-down prices, high dividend yields, and potential for market-beating returns. W.P. Carey yields 6.3% and offers growth potential through European property acquisitions, while Bristol Myers Squibb gives a 5.6% yield and has growth prospects driven by a strong drug pipeline.
Is Bristol Myers Squibb Stock a Buy?
Bristol Myers has delivered some underwhelming returns for investors in the past decade. The company's future is uncertain as it faces multiple patent cliffs.
5 Stocks I Sold Due To "Fragile Stagflation" Risk
Fragile stagflation presents challenges for investors, with limited opportunities for good returns in stocks and bonds. It is likely markets will experience a lost decade in real terms when measured from 2022. I share 5 stocks I recently sold, why I sold them, my barbell strategy, and how much cash I am holding in my investment portfolios.
You've Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever.
The pharmaceutical market is a critical part of the healthcare industry. It contributes largely to research, development, production and distribution of important life-saving vaccines and medications.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Will Bristol Myers Squibb Stock Rebound To Its 2022 Highs Of $80?
Bristol Myers Squibb stock (NYSE: BMY) currently trades at $42 per share, 47% below its pre-inflation shock high of $80 seen in June 2022. In contrast, its peer – Merck stock – is up 56% over this period.
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $42.19, denoting a -0.09% change from the preceding trading day.
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
7 Dividend Stocks to Buy Now: June 2024
Income-oriented investors love finding dividend stocks to buy now. That's particularly true when those stocks are on sale, as many continue to be.
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
Pfizer has a lot of new drugs on the market, but its stock has been beaten down. Johnson & Johnson stock is down even though both its medical technology and pharmaceutical businesses reported significant gains this year.
US FDA approves Bristol Myers' colorectal cancer therapy
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's combination therapy for treating colorectal cancer in patients with a specific gene mutation, the health regulator's website showed on Friday.
3 Warren Buffett Stocks to Buy Now: June 2024
Investors continue to look for the market to broaden before jumping in. They may be waiting awhile.
